Perioperative and Oncological Outcomes of Combined Hepatectomy with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer
- PMID: 32968959
- DOI: 10.1245/s10434-020-09165-3
Perioperative and Oncological Outcomes of Combined Hepatectomy with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer
Abstract
Background: Synchronous peritoneal and liver metastasis in colorectal cancer is a relative contraindication for curative surgery. We aimed to evaluate the safety and oncological outcomes of combined treatment of peritoneal and liver metastasis.
Methods: We conducted a retrospective analysis of metastatic colorectal cancer patients from two prospective databases: peritoneal surface malignancy (n = 536) and hepatobiliary (n = 286). We compared 60 patients treated with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) and hepatectomy; 80 patients treated with cytoreduction and HIPEC only; and 63 patients treated with hepatectomy alone.
Results: No differences in demographics were observed between the groups. Median hospital and intensive care unit (ICU) stay was shorter in group C (7 and 1 days, respectively) versus groups A and B (13 and 1 days, and 12 and 1 days, respectively; p < 0.001). Postoperative complications were not significantly different. Median follow-up was 18.6, 23.1, and 30.6 months for groups A, B, and C, respectively. Estimated 5-year overall survival (OS) was 48.8% (group A), 55.4% (group B), and 60.2% (group C) [p = 0.043 for group A vs. group C], and estimated 5-year disease-free survival (DFS) was 14.2% (group A), 23.0% (group B), and 18.6% (group C). Five-year OS was superior in group C compared with group A (p = 0.043), and DFS was superior in group C compared with groups A and B (p = 0.043 and 0.03, respectively). The peritoneum was the site of first recurrence in groups A and B (23.3% and 32.5%, respectively), and the liver was the site of first recurrence in group C (44.4%).
Conclusions: We report favorable perioperative and oncological outcomes in combined cytoreduction/HIPEC and hepatectomy for patients with peritoneal and liver metastasis. Surgical intervention after multidisciplinary discussion should be considered in patients with both peritoneal and hepatic lesions when complete cytoreduction is feasible.
Comment in
-
Response to: Concurrent or Sequential? A Curative Approach to Colorectal Liver and Peritoneal Metastasis Treatment is Possible.Ann Surg Oncol. 2021 Dec;28(Suppl 3):808-809. doi: 10.1245/s10434-021-09756-8. Epub 2021 Feb 26. Ann Surg Oncol. 2021. PMID: 33638040 No abstract available.
-
Together or Sequentially? A Curative Approach of Colorectal Liver and Peritoneal Metastasis Treatment is Possible.Ann Surg Oncol. 2021 Dec;28(Suppl 3):806-807. doi: 10.1245/s10434-021-09749-7. Epub 2021 Feb 26. Ann Surg Oncol. 2021. PMID: 33638042 No abstract available.
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262 - DOI - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590 - DOI - PubMed
-
- Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6(1):29765. https://doi.org/10.1038/srep29765 - DOI - PubMed - PMC
-
- Holch JW, Demmer M, Lamersdorf C, et al. Pattern and dynamics of distant metastases in metastatic colorectal cancer. Visc Med. 2017;33(1):70–5. https://doi.org/10.1159/000454687 - DOI - PubMed - PMC
-
- Arakawa K, Kawai K, Ishihara S, et al. Prognostic significance of peritoneal metastasis in stage IV colorectal cancer patients with R0 resection. Dis Colon Rectum. 2017;60(10):1041–9. https://doi.org/10.1097/dcr.0000000000000858 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
